86 related articles for article (PubMed ID: 24378998)
1. Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings.
Borisenko O; Beige J; Lovett EG; Hoppe UC; Bjessmo S
J Hypertens; 2014 Mar; 32(3):681-92. PubMed ID: 24378998
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
[TBL] [Abstract][Full Text] [Related]
3. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
[TBL] [Abstract][Full Text] [Related]
4. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator.
Young KC; Teeters JC; Benesch CG; Bisognano JD; Illig KA
J Clin Hypertens (Greenwich); 2009 Oct; 11(10):555-63. PubMed ID: 19817936
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
7. Incorporating patient-centered outcomes in the analysis of cost-effectiveness: imaging strategies for renovascular hypertension.
Carlos RC; Axelrod DA; Ellis JH; Abrahamse PH; Fendrick AM
AJR Am J Roentgenol; 2003 Dec; 181(6):1653-61. PubMed ID: 14627591
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
9. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective.
Roos JB; Doshi SN; Konorza T; Palacios I; Schreiber T; Borisenko OV; Henriques JP
J Med Econ; 2013; 16(3):381-90. PubMed ID: 23301850
[TBL] [Abstract][Full Text] [Related]
11. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
12. [Resistant hypertension and carotid baroreceptors stimulation].
Lantelme P; Harbaoui B; Courand PY
Presse Med; 2015; 44(7-8):730-6. PubMed ID: 26144275
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
16. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
18. Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review.
Courand PY; Feugier P; Workineh S; Harbaoui B; Bricca G; Lantelme P
Arch Cardiovasc Dis; 2014 Dec; 107(12):690-6. PubMed ID: 25445751
[TBL] [Abstract][Full Text] [Related]
19. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.
Iannazzo S; Carsi M; Chiroli S
Appl Health Econ Health Policy; 2012 Mar; 10(2):127-38. PubMed ID: 22268372
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
